MARKET

AGEN

AGEN

Agenus
NASDAQ
3.350
+0.110
+3.40%
After Hours: 3.380 +0.03 +0.90% 16:26 07/10 EDT
OPEN
3.240
PREV CLOSE
3.240
HIGH
3.385
LOW
3.100
VOLUME
833.40K
TURNOVER
--
52 WEEK HIGH
7.34
52 WEEK LOW
2.710
MARKET CAP
139.50M
P/E (TTM)
2.016
1D
5D
1M
3M
1Y
5Y
1D
Agenus Extends Debt Maturities and Warrant Expirations
TipRanks · 5d ago
Agenus issues 56,525 new warrants, sets SEC resale registration deadline within 90 days
PUBT · 5d ago
Agenus reports three-year Phase 1b BOT+BAL data at ESMO GI
TipRanks · 6d ago
Agenus Presents 3-Yr Landmark Phase 1b Data From Fully Enrolled C-800-01 Cohort Evaluating Botensilimab Plus Balstilimab In Patients With Refractory MSS mCRC Without Active Liver Metastases At ESMO GI 2026
Benzinga · 6d ago
Agenus says BOT+BAL posts 33% three-year survival in Phase 1b MSS metastatic colorectal cancer cohort without active liver metastases
PUBT · 6d ago
Weekly Report: what happened at AGEN last week (0629-0703)?
Weekly Report · 6d ago
Agenus Reports Landmark BOT+BAL Data Showing 33% Three-Year Overall Survival in Refractory MSS Metastatic Colorectal Cancer Without Active Liver Metastases at ESMO GI 2026
Barchart · 6d ago
Weekly Report: what happened at AGEN last week (0622-0626)?
Weekly Report · 06/29 10:28
More
About AGEN
Agenus Inc. is an immuno-oncology (I-O) company targeting cancer with a comprehensive pipeline of immunological agents. The company is focused on expanding patient populations benefiting from cancer immunotherapy through combination approaches, using a broad repertoire of antibody therapeutics, adoptive cell therapies (through MiNK Therapeutics) and adjuvants. Its I-O portfolio is driven by several platforms and programs, which include multiple antibody discovery platforms, antibody candidate programs, its saponin-based vaccine adjuvant platform, and a pipeline of novel allogeneic invariant natural killer T cell (iNKT) therapies for treating cancer and other immune-mediated diseases, controlled by MiNK. Its antibody candidate programs include botensilimab (BOT) and balstilimab (BAL) (a PD-1 blocking antibody). The Company has secured committed manufacturing capacity to support BOT+BAL supply needs for its clinical trials, global access programs and future commercialization.

Webull offers Agenus Inc stock information, including NASDAQ: AGEN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AGEN stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading AGEN stock methods without spending real money on the virtual paper trading platform.